PEOPLE - Exagen Diagnostics makes changes:
This article was originally published in Clinica
Executive Summary
Albuquerque, New Mexico-based prognostic testing company Exagen Diagnostics has formed an advisory board to guide the development of prognostic products in the treatment of hepatitis C infection (HCV). The board consists of four physicians: Sanjeev Arora, who has been elected chairperson, Michael Fried, Robert Gish and Paul Pockros. The board will provide input on the firm's genomic marker programmes and clinical trials that impact treatment and management of hepatitis C.